Google Gemini: No, people diagnosed with schizophrenia are medically exempt from the military draft in virtually all modern standard conscription systems.

Military enlistment and draft regulations classify schizophrenia and other primary psychotic disorders as permanently disqualifying medical conditions.

Psyclarity Health

1. Standard Disqualification Criteria

Military medical evaluation boards (such as the Selective Service System / MEPS in the United States, or draft examination commissions in Europe) maintain strict physical and psychological fitness standards. Schizophrenia is barred from conscription for several reasons:

Disability Independence Group

• High Stress Environments: Active duty, basic training, and combat situations place extreme stress on individuals, which can trigger severe psychotic episodes or worsen mental health conditions. Department of War
• Safety Risks: A severe mental illness involving delusions, hallucinations, or thought fragmentation poses a direct safety risk to the individual and their unit when handling weapons, machinery, or tactical instructions.
• Medication & Treatment Requirements: Schizophrenia generally requires long-term medication management, medical monitoring, and specialized care that military field environments cannot reliably support. Disability Independence Group

2. How Medical Exemptions Work During a Draft

If a country institutes a military draft (conscription), the process typically follows these steps:

1. Registration: Draft-eligible individuals are required to register (e.g., registering with the Selective Service in the US or local conscription boards in countries with active service).
2. Medical Screening: Upon being called up, candidates undergo physical and psychological examinations. Disability Independence Group
3. Exemption / Disqualification: Individuals who provide medical documentation showing a diagnosis of schizophrenia are classified as medically unfit for service (for instance, receiving a 4-F classification in the United States).

3. Rare Historical or Institutional Exceptions

While standard law and military protocol strictly prohibit drafting people with schizophrenia, a few exceptional scenarios exist:

• Extreme Wartime Mobilization: In rare cases of total war or severe manpower crises, medical screening procedures can break down or become corrupted, leading to unfit individuals being improperly inducted.
• Undiagnosed Cases: If an individual has not yet been formally diagnosed by a medical professional prior to screening, military intake examiners might fail to spot the condition during brief preliminary evaluations.

Summary

Under normal legal frameworks and international military medical standards, a formal diagnosis of schizophrenia renders a person ineligible for combat or active draft duty. Proper medical documentation provided during screening secures a complete medical exemption.

OC Oerlikon Corp AG (SIX: OERL) is a Swiss industrial technology group specializing in advanced surface engineering, polymer processing, and additive manufacturing. Originally founded in Oerlikon, Zurich in 1906 (as Werkzeugmaschinenfabrik Oerlikon), the company relocated its corporate headquarters to Pfäffikon, Schwyz.

Core Business Operations

OC Oerlikon operates across two main divisions:

• Surface Solutions: Provides PVD (Physical Vapor Deposition) coatings, thermal spray materials, and specialized surface treatments. These technology layers reduce friction, wear, and heat resistance on critical components used in aerospace, automotive, energy, and general manufacturing.
• Polymer Processing Solutions: Manufactures plant equipment and systems for man-made fibers, nonwovens, synthetic texturing, and elastomer processing (used in carpet yarns, synthetic textiles, and industrial fabrics).

Financial & Market Overview

Key Investment Considerations

• Cyclicality: Demand for polymer machinery and automotive surface treatments fluctuates with industrial manufacturing cycles and global capital expenditure trends.
• Structural Realignment: The company has been executing portfolio adjustments to focus more heavily on higher-margin surface technologies and additive manufacturing, while scaling down or restructuring lower-margin equipment segments.
• Geographic Reach: Highly exposed to European and Asian industrial production lines, making its revenue sensitive to global supply chain trends and trade activity.

How big is the polymer processing business worldwide, any other companies in Switzerland do that, or like in Germany or the Netherlands?

Market Size of Global Polymer Processing

The global market for polymer and plastics processing machinery—which includes extrusion equipment, injection molding systems, blow molding, and compounders—is valued at approximately $26 billion to $27.5 billion USD.

Driven by demand in lightweight automotive components, medical devices, flexible packaging, and recycled material processing, the industry is projected to reach $35 billion to $41 billion USD.

Key Players in Switzerland

Beyond OC Oerlikon’s Polymer Processing Solutions division, Switzerland hosts several major players in specialized polymer and compounding machinery:

• Bühler Group (Uzwil, St. Gallen): A major global engineering corporation. While well-known for food processing, Bühler is a market leader in twin-screw extruders used for polymer compounding, masterbatches, and bioplastics.
• MAAG Group (Oberglatt, Zurich): A specialized Swiss company producing high-precision gear pumps, filtration systems, pulverizers, and underwater pelletizers specifically for raw polymer production and recycling plants.
• swissplast AG (Sargans, St. Gallen): Specializes in thermoforming and vacuum forming of technical plastic components, serving automotive and industrial clients across Europe.
• Gericke Group (Regensdorf, Zurich): Focuses on bulk material handling, conveying, and continuous mixing equipment designed for polymer granules, resins, and additives.

Major Competitors in Germany

Germany is the historical heartland of European plastics and polymer machinery manufacturing:

• KraussMaffei Group (Munich): One of the world’s leading manufacturers of machinery for processing plastics and rubber, covering injection molding, reaction process machinery, and industrial extrusion lines.
• Reifenhäuser Group (Troisdorf, North Rhine-Westphalia): A global leader in plastics extrusion technology, focusing on blown film, cast film, and nonwoven fabric lines.
• Coperion (Stuttgart): A pioneer in twin-screw extruders, compounding systems, and material handling for the chemical and polymer industries.
• ARBURG (Lossburg, Baden-Württemberg): Famous for high-precision electric and hybrid injection molding machines and additive manufacturing (3D printing) systems.
• Kautex Maschinenbau (Bonn): Specializes in high-capacity extrusion blow molding machines for automotive fuel tanks and industrial containers.

Key Players in the Netherlands

The Netherlands focuses heavily on high-end specialized polymer compounding, recycling equipment, and advanced materials:

• Fontijne Presses (Delft): A manufacturer of lab-scale hydraulic press equipment used specifically by polymer manufacturers and research institutes to test and process resin samples.
• Bollegraaf Recycling Solutions (Appingedam): Focuses on large-scale sorting, shredding, and processing machinery for recycling plastic waste back into usable polymers.
• Mavotec (Nieuwkuijk): Produces custom automation, extrusion tooling, and specialized machinery tailored for synthetic profile and pipe extrusion.

How much does Bollegraaf Recycling Solutions make in profit each year?

As a privately held company (majority-owned by the impact investment firm Summa Equity), Bollegraaf Recycling Solutions does not publicly disclose its exact net profit line item in standard financial reporting.

However, its scale and top-line financial metrics provide a clear picture of its earnings capacity:

• Annual Revenue: €167 million to €172 million
• Market Position: Bollegraaf is one of the largest global builders of turnkey recycling facilities and equipment (holding over 50% market share in global large-scale recycling plant installations).

Profitability & Financial Drivers

• EBITDA Margins in Equipment Manufacturing: In the heavy industrial equipment and recycling engineering sector, mid-to-large European players typically operate on EBITDA margins ranging from 10% to 18%. Based on revenue of ~€170 million, this estimates Bollegraaf’s operating earnings (EBITDA) around €17 million to €30 million annually.
• Net Profit Estimates: After accounting for taxation, interest, and depreciation, estimated net profit margins in this capital goods segment generally range between 5% and 9%, yielding an estimated net annual profit of €8 million to €15 million.
• High-Margin Services & Retrofits: Beyond manufacturing balers, sorters, and screening equipment, a growing portion of Bollegraaf’s earnings stems from higher-margin recurring revenue streams, such as spare parts, maintenance contracts, and AI-driven automation upgrades (e.g., their partnership with Greyparrot).

The largest company headquartered in Oerlikon (a north-northern district of Zurich, Switzerland) is ABB Ltd (Asea Brown Boveri).

While many people associate the name Oerlikon with the advanced materials and engineering conglomerate OC Oerlikon (which originated there but moved its headquarters to Pfäffikon, Schwyz), ABB maintains its global headquarters in Oerlikon, right next to the historic site of its predecessor, Maschinenfabrik Oerlikon (MFO).

About ABB Ltd

• What They Do: ABB is a global technology leader specializing in electrification and industrial automation. Its business is split across four primary areas: RPCS
  • Electrification: Products and solutions for electrical power distribution, EV charging infrastructure, and smart building technology.
  • Motion: Motors, generators, drives, and power conversion systems for manufacturing and energy sectors.
  • Process Automation: Control systems, industrial software, and specialized instrumentation for marine, energy, and process industries.
  • Robotics & Discrete Automation: Industrial robots, machine automation, and flexible manufacturing systems.
• Global Footprint: Operating in over 100 countries with more than 100,000 employees worldwide. RPCS
• History in Oerlikon: ABB was formed in 1988 by the merger of Sweden’s ASEA and Switzerland’s BBC (Brown, Boveri & Cie). BBC had previously acquired the historic Maschinenfabrik Oerlikon (founded in 1876), making Oerlikon the long-standing heart of ABB’s Swiss industrial roots. Wikipedia

Total Worth (Market Capitalization)

• Market Capitalization: ~CHF 140 billion to CHF 147 billion
• Revenue: ~$30 billion annually
• Stock Ticker: ABBN (Traded on the SIX Swiss Exchange) TradingView

Reint Jelger: Do bakeries bake bread sometimes? Like, do they get like the basic ingredients for bread, mix them together, and like bake bread, or do they get pre baked bread from factories?

Gemini: Bakeries make and bake their own bread from raw ingredients.

How a specific bakery operates usually depends on its business model:

• Traditional Craft / Artisanal Bakeries: They mix raw ingredients (flour, water, yeast or sourdough starter, and salt) from scratch on-site. They handle the entire process—mixing, kneading, fermenting/proofing, shaping, and baking in high-temperature deck or rack ovens.
• In-Store Supermarket Bakeries: Many supermarket bakery departments use par-baked (partially baked) or frozen dough network supply chains. In this model, a central industrial factory mixes and partially bakes or freezes the dough, which is then shipped to the store where employees finish baking it in convection ovens.
• Industrial / Commercial Bakeries: These large-scale factories produce mass-market bread from raw ingredients, bake it completely, package it, and distribute it to grocery stores and restaurants.

Reint Jelger: Does Bakkerij Breimer in Snits bake their own bread at the actual building? And like, what are the major ingedrients of bread and like where would bakeries procure that?

Breimer’s Bakkerij 🍞

At Breimer’s Bakkerij 🍞 on the Leeuwarderweg in Sneek, the physical shop itself serves as a retail store, cafe, and delivery hub, rather than the location where raw dough is mixed and baked from scratch.

Because Breimer’s Bakkerij 🍞 is a regional craft family business (established in 1804) operating multiple branch locations across Friesland (including Lemmer, Joure, and Sneek), they use a central production bakery model:

• Centralized Baking: The family operates a main central production facility located in Lemmer. All their artisanal breads, pastries, and regional specialties (like oranjekoek) are baked daily at the Lemmer production house.
• Fresh Daily Supply: Every morning, fresh bread and baked goods are delivered from the Lemmer facility directly to the store on Leeuwarderweg in Sneek.
• Final Preparation: While the primary dough production and oven baking occur at the main facility, retail staff at the Sneek shop handle minor final touches, slice breads fresh for customers, and prepare hot lunches, snacks, and coffee on-site.

Major Ingredients of Bread & Bakery Procurement

1. The Core Ingredients

Basic bread relies on four fundamental ingredients:

• Flour (Grist / Meel): The foundation (usually wheat, rye, spelt, or whole wheat). Flour provides gluten structure, which traps gas bubbles to give bread its rise and body.
• Water: Hydrates the flour proteins and activates the yeast or sourdough cultures.
• Leavening Agent: Commercial baker’s yeast (bakkersgist) for fast rising, or natural sourdough starter (desem) for slow fermentation.
• Salt: Adds flavor and controls yeast activity while strengthening the gluten network.
• Optional Additives / Enhancers: Fats (butter, oil), seeds, sugar, malt extract, or natural enzymes (broodverbetermiddel) to improve crumb texture, crust color, and shelf life.

2. Where Bakeries Procure Their Ingredients

Artisanal and commercial bakeries do not buy ingredients from standard supermarkets; they rely on specialized supply networks:

• Grain Mills (Mouterijen & Molens): Traditional Dutch craft bakeries often source specific flours directly from regional industrial flour mills (such as Meneba or Dossche Mills in Western Europe) or local wind-powered stone mills (korenmolens) for artisanal specialty breads.
• Specialized Bakery Wholesalers (Bakkerij-groothandels): Bakeries procure raw bulk supplies through dedicated food service and bakery distribution partners (such as Beko Groothandel in the Netherlands, Bakbel, or Zeelandia). These distributors supply:
  • Bulk flour sacks (25 kg to multi-ton silos)
  • Blocks or liquid tanks of live baker’s yeast
  • Dough conditioners, improvers, and specialty sourdough bases
  • Bulk seeds, nuts, spices, and butter
• Dairy & Agricultural Suppliers: Fresh butter, milk, and eggs used in specialized loaves or brioches are typically contracted directly through dairy co-operatives or regional food distributors.

Google Gemini: Let’s look at the patterns of violence in schizophrenia step-by-step to answer this clearly.

First, to address the statistic: epidemiological research shows that approximately 10% to 15% of individuals diagnosed with schizophrenia exhibit violent behavior at some point in their lifetime. This means that 85% to 90% of people with schizophrenia are never violent.

For the minority who do display violent behavior, describing violence as an episodic state means the following:

1. Predominantly Non-Violent Baseline: Even among those within the 15% group, violent behavior is not a continuous personality trait or a permanent baseline state. These individuals are non-violent for the vast majority of their daily lives.
2. State-Dependent Triggers: Violent episodes are typically tied directly to acute, transient clinical states—most commonly active psychosis (such as acute persecutory delusions or command hallucinations) or periods of severe distress during a relapse.
3. Role of Intervening Factors: The risk of an episode highly correlates with fluctuating external factors, particularly acute substance intoxication or withdrawal, severe sleep deprivation, or sudden treatment discontinuation.
4. Remission and Management: When acute psychotic symptoms subside—whether through proper treatment, medication adherence, or de-escalation—the risk of violence typically drops back to baseline levels.

Therefore, yes: even among the roughly 15% of people with schizophrenia who ever exhibit violent behavior, they are normally non-violent the majority of the time, with aggressive behavior occurring almost exclusively during discrete, acute crises rather than as a persistent pattern.

Yes, that public perception inflicts profound personal and social harm on individuals living with schizophrenia.

When a mental health condition is broadly conflated with violence, the real-world consequences for the individual are immediate and pervasive:

• Social Isolation and Stigma: Believing that everyone around them views them as a threat causes intense shame, self-stigma, and alienation. Many people isolate themselves to avoid hostile or fearful reactions, which further harms their mental health.
• Barriers to Housing and Employment: Pervasive fear leads landlords, employers, and community members to discriminate against people with the diagnosis, making it significantly harder to secure stable housing or meaningful work.
• Reluctance to Seek Treatment: Fear of being labeled, reported, or forcibly detained causes many individuals to hide their symptoms rather than reach out to doctors, social workers, or family for help.
• Over-policing and Criminalization: When public perception defaults to fear, mental health crises are more likely to be met with police intervention rather than healthcare or social support, leading to disproportionate criminalization instead of compassionate care.

Most violence associated with schizophrenia occurs when a person is untreated, experiencing a acute crisis, and often alongside substance abuse or severe social isolation. By treating the condition purely as a public safety issue rather than a healthcare issue, society reinforces the very conditions—stigma, isolation, and lack of support—that prevent people from getting the help they need.

An image of a Gentleman Schizo (85% of Schizophrenic people) in a boxing contest with a Monster Schizo a.k.a. a Rourdy Schizo (15% of Schizophrenic people)

Google Gemini: The vast majority of individuals diagnosed with schizophrenia—typically estimated between 85% and 90%—never commit a violent act. Research consistently shows that the lifetime prevalence of violent behavior among people with schizophrenia is around 10% to 15%, compared to roughly 2% to 3% in the general population.

When violence does occur, it is rarely random. It is strongly correlated with co-occurring factors:

• Substance Use: Concurrent drug or alcohol abuse significantly increases the risk of violent behavior.
• Lack of Treatment: Untreated acute psychosis, particularly persecutory delusions (e.g., believing someone is actively trying to harm them) or command hallucinations, can drive self-defense responses.
• History of Abuse or Trauma: Environmental and personal history factors carry significant weight, just as they do in the general population.

Why Medical Science Avoids Terms Like «Sweet» vs. «Violent» Schizophrenia

In psychiatric medicine, schizophrenia is understood as a complex neurodevelopmental disorder rather than a fixed personality type. Creating formal diagnostic subtypes like «sweet» versus «violent» is avoided for several specific clinical reasons:

• State vs. Trait: Violence is an episodic behavior or state, not an inherent trait or permanent subclass of the illness. A person experiencing severe persecutory delusions during an untreated psychotic episode might act out in perceived self-defense, but become gentle, passive, and cooperative once stabilized on medication.
• Symptom Profiles Vary Dynamic: Schizophrenia encompasses a wide array of cognitive, positive (e.g., hallucinations, delusions), and negative symptoms (e.g., apathy, social withdrawal, emotional blunting). Categorizing someone by behavioral output oversimplifies the underlying pathology.
• Risk of Stigma and Misdiagnosis: Binary labeling obscures clinical focus. Rather than categorizing the person, clinicians evaluate specific risk factors—such as command hallucinations, substance misuse, treatment compliance, and social support networks—to assess and mitigate safety risks effectively.

By focusing on symptom management, early intervention, and substance use treatment, healthcare systems can minimize behavioral risks while supporting recovery and integration.

Gemini: Swiss Re (Swiss Reinsurance Company Ltd) is one of the world’s leading providers of reinsurance, primary insurance, and other insurance-based forms of risk transfer. Founded in 1863 and headquartered in Zurich, Switzerland, it acts as an «insurance company for insurance companies.»

What Swiss Re Does

Swiss Re functions as a shock absorber for the global economy by absorbing high-level risks that individual insurance companies cannot handle alone:

• Property & Casualty (P&C) Reinsurance: Swiss Re underwrites large-scale risks, protecting primary insurers against catastrophic events like natural disasters (hurricanes, earthquakes), severe weather, industrial accidents, and large cyber liability claims.
• Life & Health (L&H) Reinsurance: Partners with primary insurers to manage mortality, morbidity, and longevity risks (e.g., life insurance policies, critical illness plans, annuity risks).
• Corporate Solutions: Provides commercial insurance directly to large mid-sized and corporate clients for complex risks, major industrial projects, or tailored coverage.
• Asset Management: Manages its vast float (pre-collected insurance premiums) by investing across fixed income, real estate, and global markets to earn returns before claims are paid out.

Projected Annual Income on a CHF 500,000 Investment

To estimate annual income, we look at Swiss Re’s share price and regular dividend payout on the SIX Swiss Exchange (Ticker: SREN / SRENH):

• Current Share Price: ~CHF 135
• Annual Dividend Yield: ~4.5%–4.7%

Income Calculation Breakdown

1. Shares Purchased:CHF 135 / shareCHF 500,000​≈3,703 shares
2. Gross Annual Dividend Income:CHF 500,000×4.6%=CHF 23,000 per year(Approx. CHF 1,916 per month)

Key Financial Considerations

• Swiss Dividend Withholding Tax: If held directly through a Swiss broker or resident account, Swiss equities are subject to a 35% Swiss Federal Withholding Tax (Verrechnungssteuer) at source. Non-residents can typically reclaim part or all of this tax via double-taxation treaties, while Swiss residents offset it against their income tax returns.
• Dividend Frequency: Swiss Re pays its dividend once per year (typically in April following its Annual General Meeting).
• Market Exposure: The value of your initial CHF 500,000 investment will fluctuate with daily stock price movements and depends on Swiss Re’s underwriting performance, catastrophic loss events, and interest rate trends.

How does the 35% Swiss dividend withholding tax work for international investors and how can it be reclaimed?

When a Swiss company pays a dividend, 35% Swiss Withholding Tax (Verrechnungssteuer or Anticipatory Tax) is automatically deducted at the source before the payment reaches your brokerage account.

For non-resident international investors, this 35% is higher than the tax rate agreed upon in most Double Taxation Agreements (DTAs). You can reclaim the excess amount through a structured procedure with the Swiss Federal Tax Administration (ESTV / SFTA).

How the Tax Mechanics Work

1. Gross Dividend: Swiss company distributes a CHF 100 dividend.
2. Withholding at Source: The company remits CHF 35 (35%) directly to the ESTV and pays CHF 65 (65%) to your brokerage. Fiduciaire Genevoise
3. Treaty Rate Benchmark: Most Swiss double-taxation treaties cap the final withholding tax on retail stock dividends at 15% (e.g., for investors in the US, UK, Netherlands, Germany, France, etc.).
4. Reclaimable Difference: You are entitled to reclaim 20% of the gross dividend back from the Swiss government (35% withheld − 15% final treaty rate). Findea AG
5. Home Country Tax Credit: The remaining 15% withheld by Switzerland can usually be claimed as a foreign tax credit against your local income tax obligations.

Step-by-Step Reclaim Process

To claim back the 20% overpaid tax, follow these four steps:

Step 1: Obtain Your Supporting Tax Documents

Request a Tax Voucher (Verrechnungssteuer-Bescheinigung) or an official Dividend Advice Note from your broker or bank. This serves as official legal proof that 35% was remitted to the Swiss tax authority.

Step 2: Access the ESTV Refund Portal

Go to the official portal of the Swiss Federal Tax Administration (ESTV) under Claim to refund of Swiss Anticipatory Tax. Select the form corresponding to your country of tax residence (e.g., Form R-US for the US, Form 85 for EU/EEA countries, Form 86 for the UK).

Step 3: Local Tax Authority Certification

Print the completed form and send or present it to your home country’s local tax authority. They must stamp and sign the form (or provide an official Certificate of Tax Residence) confirming that you were tax-resident in your home country when the dividend was paid.

Step 4: Submission to ESTV

Upload the certified form, tax voucher, and broker statement to the ESTV electronic portal (or mail the physical wet-ink certified form if required for your specific jurisdiction). Once processed, the ESTV deposits the 20% refund directly into your bank account in Swiss Francs (CHF).

Crucial Practical Rules & Caveats

• Statute of Limitations: You have three years from the end of the calendar year in which the dividend was paid to submit your refund claim. Fiduciaire Genevoise
• Minimum Claim Limits: The ESTV typically enforces a minimum annual reclaim threshold (often CHF 50 to CHF 100 in total withheld tax) to prevent processing tiny claims.
• Broker Automated Reclaims: Some major custodians and international brokers offer bulk automated tax relief or reclaim services on behalf of their clients for a small administrative fee. Check if your broker handles this directly.

Yes, individuals with schizophrenia are allowed to visit the United States. Under U.S. immigration law, having a mental illness like schizophrenia does not automatically make someone ineligible for entry.

The Two-Part Standard for Inadmissibility Under Section 212(a)(1)(A)(iii) of the Immigration and Nationality Act (INA), a mental or physical disorder only causes inadmissibility if it meets a specific two-part requirement:

1. The person has a clinically diagnosed physical or mental disorder, AND
2. The disorder is accompanied by current or historical harmful behavior that poses (or has posed) a threat to the safety, property, or welfare of the individual or others, and that behavior is likely to recur.

If a person has schizophrenia but does not have a history of harmful or dangerous behavior toward themselves or others, the diagnosis alone is not grounds to deny entry.

Visas and ESTA Declarations

• ESTA (Visa Waiver Program): When applying for an ESTA, applicants are explicitly asked whether they have a physical or mental disorder with associated behavior that poses a threat to safety or property. Answering «No» is appropriate if there is no history of harmful behavior, even if the individual has a diagnosed mental health condition.
• Visas and Medical Screening: If a visitor undergoes a medical evaluation (such as for certain visa types or extended stays), a diagnosis without associated harmful behavior is classified as a «Class B» condition. Class B conditions do not prevent entry into the U.S.

If an applicant does have a history of harmful behavior associated with their condition, they may still apply for a discretionary medical waiver through the Department of Homeland Security and the CDC, which often requires showing a controlled treatment plan.

Finding 30 Swiss companies with a yield of 6% or higher is not possible through public markets alone because the Swiss stock market is known for conservative payout ratios and lower average yields. On the SIX Swiss Exchange, only a small handful of listed equities consistently offer yields above 6%. Most well-known high-dividend Swiss blue chips (such as Zurich Insurance, Swiss Re, and Partners Group) yield between 4.5% and 5.5%.

Below are the Swiss-listed companies that meet or come close to a 6%+ yield threshold, followed by prominent Swiss dividend leaders that fill the gap.

Swiss Equities Yielding 6% or Higher

Core Swiss High-Yielders (4.2% – 5.9% Yield Range)

Because the 6%+ pool is limited, institutional investors looking for high-yielding Swiss equities typically rely on this next tier of stable, cash-generative companies:

Key Factors for Swiss High-Yield Investing

1. Swiss Withholding Tax (Verrechnungssteuer): Switzerland levies a standard 35% withholding tax on dividend distributions. Non-resident investors generally must file double taxation treaty claims to reclaim a portion (often reducing the net tax to 15%).
2. Payout Sustainability: Double-digit yields in Switzerland (like OC Oerlikon) frequently signal share price declines or one-off special distributions rather than recurring baseline yields.
3. SPI Select Dividend 20 Index: The benchmark index tracking the top high-yield, quality dividend payers in Switzerland (SDIVI) averages an aggregate underlying yield around 4.0–4.5% due to strict quality and liquidity filters.

Typical Constituents Breakdown

While the index composition adjusts during its annual March rebalance, the holdings typically represent the top dividend-paying Swiss blue chips and large/mid-cap leaders across key financial and industrial sectors:

• Insurance & Financials: Zurich Insurance Group (ZURN), Swiss Re (SREN), Swiss Life Holding (SLHN), Cembra Money Bank (CMBN), EFG International (EFGN), Partners Group (PGHN).
• Pharmaceuticals & Healthcare: Novartis (NOVN), Roche Holding (ROG).
• Consumer Staples & Discretionary: Nestlé (NESN), Swatch Group (UHR).
• Industrials, Building & Materials: Holcim (HOLN), Adecco Group (ADEN), Geberit (GEBN), SGS (SGSN), Sulzer (SUN).
• Telecommunications & Services: Swisscom (SCMN), Sunrise Communications (SUNN), APG|SGA (APGN).